Role of IGF-I in skeletal muscle mass maintenance

Trends in Endocrinology and Metabolism

Volumn 20, Issue 7, 2009, Pages 349-356

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUSCLE RING FINGER 1 PROTEIN; MYOCYTE ENHANCER FACTOR 2; MYOD PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; RAS PROTEIN; S6 KINASE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR MAF; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE DELETION; HUMAN; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE INJURY; MUSCLE MASS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE SATELLITE CELL;

ANIMALS; HUMANS; HYPERTROPHY; INSULIN-LIKE GROWTH FACTOR I; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; RECEPTOR CROSS-TALK; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 69949091564     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.04.002     Document Type: Review

References (88)

1. Laurence, M.D. et al. (2007) Insulin receptor structure and its implications for the IGF-I receptor. 17, 699-701
2. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
3. Hawke T.J., and Garry D.J. Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 91 (2001) 534-551
4. Florini J.R., et al. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17 (1996) 481-517
5. Rennie M.J., et al. Control of the size of the human muscle mass. Annu. Rev. Physiol. 66 (2004) 799-828
6. Bassel-Duby R., and Olsen E.N. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75 (2006) 19-37
7. Svanberg E., et al. IGF-I/IGFBP-3 binary complex modulates sepsis-induced inhibition of protein synthesis in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 279 (2000) 1145-1158
8. Glass D., and J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell. Biol. 37 (2005) 1974-1984
9. Coleman M.E., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270 (1995) 12109-12116
10. Musaro A., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27 (2001) 195-200
11. Seale P., et al. Adult stem cell specification by Wnt signaling in muscle regeneration. Cell Cycle 2 (2003) 418-419
12. Parker M.H., et al. Looking back to the embryo: defining transcriptional networks in adult myogenesis. Nat. Rev. Genet. 4 (2003) 497-507
13. Hill M., et al. Muscle satellite (stem) cell activation during local tissue injury and repair. J. Anat. 203 (2003) 89-99
14. Barton-Davis E.R., et al. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand. 167 (1999) 301-305
15. Edwall D., et al. Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. Endocrinology 124 (1989) 820-825
16. DeVol D., et al. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am. J. Physiol. 259 (1990) 89-95
17. Yang S., et al. Cloning and characterization of an IGF-I isoform expressed in skeletal muscle subjected to stretch. J. Muscle Res. Cell Motil. 17 (1996) 487-495
18. Bamman M.M., et al. Cluster analysis tests the importance of myogenic gene expression during myofiber hypertrophy in humans. J. Appl. Physiol. 102 (2007) 2232-2239
19. Rosenblatt J.D., and Parry D.J. Gamma irradiation prevents compensatory hypertrophy of overloaded mouse extensor digitorum longus muscle. J. Appl. Physiol. 73 (1992) 2538-2543
20. Engert J.C., et al. Proliferation precedes differentiation in IGF-I stimulated myogenesis. J. Cell Biol. 135 (1996) 431-440
21. McCormick K.M., and Thomas D.P. Exercise-induced satellite cell activation in senescent soleus muscle. J. Appl. Physiol. 72 (1992) 888-893
22. Chakravarthy M.V., et al. IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. J. Appl. Phyiol. 89 (2000) 1365-1379
23. Adi S., et al. Early stimulation and late inhibition of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: a potential mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. Endocrinology 143 (2002) 511-516
24. Mukherjee A., et al. Insulin-like growth factor (IGF) binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions. Mol. Endocrinol. 22 (2008) 206-215
25. Foulstone E.J., et al. Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. J. Cell. Physiol. 189 (2001) 207-215
26. Coolican S.A., et al. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 272 (1997) 6653-6662
27. Jacquemin V., et al. IL-3 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes. J. Cell Sci. 120 (2007) 670-681
28. James P.L., et al. Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism. J. Cell Biol. 133 (1996) 683-693
29. Tureckova J., et al. Insulin-like growth factor-mediated muscle differentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J. Biol. Chem. 276 (2001) 39264-39270
30. Sacheck J.M., et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MURF-1. Am. J. Physiol. Endocrinol. Metab. 287 (2004) 591-601
31. Machida S., et al. Forkhead transcription factor FOXO1 transduces insulin-like growth factors signal to p27kip in primary skeletal muscle satellite cells. J. Cell. Physiol. 196 (2003) 523-531
32. Liu J.P., et al. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (Igf-1) and type 1 IGF receptor (Igf-r). Cell 75 (1993) 59-72
33. Fernandez A.M., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15 (2001) 1926-1931
34. Lai K.M., et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol. Cell. Biol. 24 (2004) 9295-9304
35. Sugita H., et al. Burn injury impairs insulin-stimulated Akt/PKB activation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E585-E591
36. Luo J., et al. Loss of class 1A PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 3 (2006) 355-366
37. Pallafacchina G., et al. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. U. S. A. 25 (2001) 25
38. Ohanna M., et al. Atrophy of S6K1 -/- skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7 (2005) 286
39. Hara K., et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272 (1997) 26457-26463
40. Latres E., et al. IGF-I inversely regulates atrophy-induced genes via the PI3K/Akt/mTOR pathway. J. Biol. Chem. 280 (2005) 2737-2744
41. Rommel C., et al. Mediation of IGF-I induced skeletal myotube hypertrophy by PI3K/Akt/mTOR and PI3K/Akt/GSK3 pathways. Nat. Cell Biol. 3 (2001) 1009-1013
42. Coleman M.E., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270 (1995) 1209-1216
43. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 4 (2002) 648-657
44. Wackerhage H., and Rennie M.S. How nutrition and exercise maintain the human musculoskeletal mass. J. Anat. 208 (2006) 451-501
45. Hahn-Windgassen A., et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280 (2005) 32081-32089
46. Kubica N., et al. Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2B{epsilon}mRNA in a mammalian target of rapamycin-dependent manner. J. Biol. Chem. 280 (2005) 7570-7580
47. van der Velden J.L., et al. Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. Am. J. Physiol. Cell Physiol. 290 (2006) C453-C460
48. Machida S., and Booth F.W. Insulin-like growth factor I and muscle growth: implication for satellite cell proliferation. Proc. Nutr. Soc. 63 (2004) 337-340
49. McKoy G., et al. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J. Physiol. 516 (1999) 583-592
50. Shavlakadze T., et al. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm. IGF Res. 15 (2005) 4-18
51. Musaro A., et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1206-1210
52. Pelosi L., et al. Local expression of IGF-I accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J. 21 (2007) 1393-1402
53. Musaro A., et al. The role of local insulin-like growth factor-1 isoforms in the pathophysiology of skeletal muscle. Curr. Genomics 3 (2002) 149-162
54. Paul A.C., and Rosenthal N. Different modes of hypertrophy in skeletal muscle fibers. J. Cell Biol. 156 (2002) 751-760
55. Jennische E. Expression and localization of IGF-binding protein mRNAs in regenerating rat skeletal muscle. APMIS 108 (2000) 747-755
56. Gayan-Ramirez G., et al. Acute treatment with corticosteroids decreases IGF-I and IGF-2 expression in the rat diaphragm and gastrocnemius. Am. J. Resp. Crit. Care Med. 159 (1999) 283-289
57. Reardon K.A., et al. Myostatin, insulin-like growth factor-I, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy. Muscle Nerve 2 (2001) 893-899
58. Frost R.A., and Lang C.H. Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 255-263
59. Lang C.H., et al. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, e1F4E availability, and myostatin in alcohol-fed rats. Am. J. Physiol. Endocrinol. Metab. 286 (2004) 916-926
60. Lang C.H., et al. Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2005) R963-R972
61. Lang C.H., et al. Beta-adrenergic blockade exacerbates sepsis-induced changes in tumor necrosis factor alpha and interleukin-6 in skeletal muscle and is associated with impaired translation initiation. J. Trauma 64 (2008) 477-486
62. Frost R.A., and Lang C.H. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J. Appl. Physiol. 103 (2007) 378-387
63. Schakman O., et al. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146 (2005) 1789-1797
64. Hamel F.G., et al. Inhibition of proteasome activity by selected amino acids. Metabolism 52 (2003) 810-814
65. Bodine S.C., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001) 1704-1708
66. Gomes M.D., et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14440-14445
67. Lecker S.H. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18 (2004) 39-51
68. Clarke B.A., et al. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6 (2007) 376-385
69. Stitt T.N., et al. The IGF-I/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14 (2004) 395-403
70. Sandri M., et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399-412
71. Li B.G., et al. Insulin-like growth factor-I blocks dexamethasone-induced protein degradation in cultured myotubes by inhibiting multiple proteolytic pathways: 2002 ABA paper. J. Burn Care Rehab. 25 (2004) 112-118
72. Schakman O., et al. Insulin-like growth factor-1 gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146 (2005) 1789-1797
73. Shah O.J., et al. Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. Biochem. J. 347 (2000) 389-397
74. Liu Z., et al. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 287 (2004) 275-281
75. d Alvaro C., et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J. Biol. Chem. 279 (2004) 17070-17078
76. Mourkioti F., et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 116 (2006) 2945-2954
77. Cai D., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119 (2004) 285-298
78. Doborwolny G., et al. Muscle expression of a local IGF-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 168 (2005) 193-199
79. Miller T.M., and Cleveland D.W. Has gene therapy for ALS arrived? Nat. Med. 9 (2003) 1256-1257
80. Barton E.R., et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157 (2002) 137-148
81. Haddad F., and Adams G.R. Selected contribution: acute cellular and molecular responses to resistance exercise. J. Appl. Physiol. 93 (2002) 294-403
82. Haddad F., and Adams G.R. Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J. Appl. Physiol. 100 (2005) 1188-1203
83. Anderson B.C., et al. Increased extraocular muscle strength with direct injection of insulin-like growth factor-I. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2461-2467
84. Hameed M., et al. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J. Physiol. 547 (2003) 247-254
85. Fryburg D.A. Insulin-like growth factor I exerts growth hormone- and insulin like actions on human muscle protein metabolism. Am. J. Physiol. 267 (1994) 331-336
86. Liu Z., et al. The regulation of body and skeletal muscle protein metabolism by hormones and amino acids. J. Nutr. 136 (2006) 212S-221S
87. Debroy M.A., et al. Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J. Trauma 47 (1999) 904-910
88. Hatton J., et al. Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. J. Neurosurg. 105 (2006) 843-852